Topline overall survival results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy.
A new study examines the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer that is known to extend lifespan.
The Association of Cancer Care Centers and LUNGevity have launched the Electronic Health Records Integrations for Biomarker Testing: Roadmap, a new virtual resource to support multidisciplinary cancer care teams prepare, implement, and evaluate electronic health record integrations for biomarker testing.
Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence model to improve the detection of breast cancer metastasis, which could reduce the need for needle or surgical biopsies.
Orca Bio will present new data at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.
A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.
The Menarini Group and Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, will present updated results from phase Ib/II ELECTRA and ELEVATE clinical studies evaluating elacestrant (Orserdu) in combination with other treatments at the 2024 American Society of Clinical Oncology on June 2.
Updated clinical data from a phase Ib combination cohort evaluating vepdegestrant, an investigational oral proteolysis targeting chimera estrogen receptor degrader, in combination with palbociclib (Ibrance) are consistent with data presented at the San Antonio Breast Cancer Symposium in December 2023.
The National Comprehensive Cancer Network has published NCCN Guidelines for Patients: Small Bowel Adenocarcinoma.
The National Comprehensive Cancer Network took part in two events in Warsaw focused on advancing cancer care and highlighting the Poland-US bilateral achievements in health care May 21-22.
